Recombinant Human EGLN2 Protein，His

EGLN2, also known as Egl-9 family hypoxia-inducible factor 2, plays a crucial role in cellular responses to hypoxia by regulating the stability of hypoxia-inducible factors (HIFs). As an important oxygen-sensing enzyme, EGLN2 belongs to the prolyl hydroxylase domain (PHD) family and is primarily involved in the post-translational modification of HIF-α subunits, facilitating their degradation under normoxic conditions. When oxygen levels are low, EGLN2 activity decreases, leading to the stabilization and accumulation of HIFs, which then activate numerous genes involved in adaptive responses such as angiogenesis, erythropoiesis, and metabolism. Research on EGLN2 recombinant protein has gained traction due to its potential implications in various pathophysiological conditions, including cancer, ischemic diseases, and metabolic disorders. Understanding the structure and function of EGLN2 through recombinant protein studies provides insights into its catalytic mechanism and interaction with HIFs, which could aid in the development of targeted therapies that manipulate the hypoxic response. Furthermore, due to its role in tumor progression and metastasis, EGLN2 is being explored as a possible therapeutic target for cancer treatment. Overall, the study of EGLN2 recombinant protein not only enhances our comprehension of hypoxic signaling pathways but also opens up avenues for innovative interventions in diseases associated with dysregulated oxygen homeostasis.